Viking Therapeutics logo

Viking TherapeuticsNASDAQ: VKTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

28 April 2015

Next earnings report:

07 February 2025

Last dividends:

N/A

Next dividends:

N/A
$5.74 B
-42%vs. 3y high
89%vs. sector
-vs. 3y high
-vs. sector
-78%vs. 3y high
86%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 11 min ago
$51.51+$0.02(+0.04%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

VKTX Latest News

VKTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Viking Therapeutics, Inc.
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.

Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheers
marketwatch.com20 November 2024 Sentiment: POSITIVE

The biotech's liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.

3 Things You Need to Know if You Buy Viking Therapeutics Today
fool.com18 November 2024 Sentiment: NEUTRAL

3 Things You Need to Know if You Buy Viking Therapeutics Today

Is It Too Late to Buy Viking Therapeutics Stock?
fool.com17 November 2024 Sentiment: NEUTRAL

Is It Too Late to Buy Viking Therapeutics Stock?

ATTENTION VKTX SHAREHOLDERS: Investors who lost money on Viking Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
accesswire.com16 November 2024 Sentiment: NEUTRAL

NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.

Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
fool.com16 November 2024 Sentiment: POSITIVE

Mergers and acquisitions could make a comeback with Trump headed back to Washington.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
accesswire.com16 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Viking Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viking Therapeutics, Inc. (VKTX)
accesswire.com14 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
accesswire.com14 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

VKTX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Viking Therapeutics, Inc. Shareholders Who Lost Money
accesswire.com14 November 2024 Sentiment: NEUTRAL

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.

What type of business is Viking Therapeutics?

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

What sector is Viking Therapeutics in?

Viking Therapeutics is in the Healthcare sector

What industry is Viking Therapeutics in?

Viking Therapeutics is in the Biotechnology industry

What country is Viking Therapeutics from?

Viking Therapeutics is headquartered in United States

When did Viking Therapeutics go public?

Viking Therapeutics initial public offering (IPO) was on 28 April 2015

What is Viking Therapeutics website?

https://www.vikingtherapeutics.com

Is Viking Therapeutics in the S&P 500?

No, Viking Therapeutics is not included in the S&P 500 index

Is Viking Therapeutics in the NASDAQ 100?

No, Viking Therapeutics is not included in the NASDAQ 100 index

Is Viking Therapeutics in the Dow Jones?

No, Viking Therapeutics is not included in the Dow Jones index

When was Viking Therapeutics the previous earnings report?

No data

When does Viking Therapeutics earnings report?

The next expected earnings date for Viking Therapeutics is 07 February 2025